Apalutamide and Metastasis-free Survival in Prostate Cancer

Dr. Rachner reports receiving lecture fees from Amgen and Roche and fees for serving on an advisory board from Merck; Dr. Tsourdi, receiving lecture fees from Amgen; and Dr. Hofbauer, receiving lecture fees and educational material from Alexion, Amgen, Merck, Roche, and Shire, provided to his institution and himself, and grant support from Amgen and Novartis, paid to his institution. No other potential conflict of interest relevant to this letter was reported.